Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.51 |
| ▸ | L3MBTL3 | Q96JM7 | 8/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 0.48 |
| ▸ | MBTD1 | Q05BQ5 | 2/20 | 0.48 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.48 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061061 | 0.91 | HRH3 (0.49) | HRH3L3MBTL3L3MBTL1CYP2D6KDM4E | |
| Hydrochloric Acid SCHEMBL27808139 | 0.90 | HRH3 (0.48) | HRH3L3MBTL3L3MBTL1CYP2D6KDM4E | |
| SCHEMBL3062784 | 0.81 | HRH3 (0.53) | HRH3L3MBTL3L3MBTL1MBTD1MCHR1 | |
| SCHEMBL3066125 | 0.80 | TRPV6 (0.41) | HRH3KDM4E | |
| SCHEMBL3061021 | 0.79 | HSD11B1 (0.49) | HRH3 | |
| SCHEMBL3056229 | 0.76 | KDM2B (0.41) | — | |
| Hydrochloric Acid SCHEMBL27786263 | 0.76 | KDM2B (0.40) | — | |
| SCHEMBL3051150 | 0.75 | KDM2B (0.41) | HRH3MCHR1CYP2D6KDM4ETSHR | |
| SCHEMBL3061772 | 0.75 | CHKA (0.53) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E | |
| SCHEMBL3057319 | 0.74 | TRPV6 (0.46) | HRH3L3MBTL3L3MBTL1MBTD1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | claimed |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | claimed |
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-8344001-B2 | Heterocyclic H3 antagonists | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-10-21 | — | — | US | disclosed |
| EP-2166850-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | High Point Pharmaceuticals, LLC (US) | 2010-03-31 | — | — | EP | disclosed |
| EP-2014656-A2 | New heteocyclic h3 antagonists | TRANSTECH PHARMA (US) | 2009-01-14 | — | — | EP | disclosed |
| EP-2014656-A2 | New heteocyclic h3 antagonists | TRANSTECH PHARMA (US) | 2009-01-14 | — | — | EP | disclosed |
| WO-2008154126-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154126-A1 | NEW HETEOCYCLIC H3 ANTAGONISTS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267721-A1 | Heterocyclic H3 Antagonists | HRH3, HRH4, HRH2 | HRH3 1/4885L3MBTL3 1311/4885L3MBTL1 2451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.